Financials data is unavailable for this security.
View more
Year on year Altimmune Inc had net income fall 4.41% from a loss of 84.71m to a larger loss of 88.45m despite a -- increase in revenues from -68.00k to 426.00k.
| Gross margin | -- |
|---|---|
| Net profit margin | -24,778.97% |
| Operating margin | -26,822.01% |
| Return on assets | -56.83% |
|---|---|
| Return on equity | -63.29% |
| Return on investment | -61.41% |
More ▼
Cash flow in USDView more
In 2023, Altimmune Inc increased its cash reserves by 21.62%, or 24.03m. Cash Flow from Financing totalled 86.11m or 20,212.44% of revenues. In addition the company used 75.81m for operations while cash from investing totalled 13.73m.
| Cash flow per share | -1.26 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.15 |
|---|---|
| Tangible book value per share | 2.15 |
More ▼
Balance sheet in USDView more
| Current ratio | 11.30 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
